elizabeth quiroz

Dr. elizabeth quiroz


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
PMPedro Pablo Martínez-Rojas
Pedro Pablo Martínez-Rojas
EQelizabeth quiroz
elizabeth quiroz
VMVERONICA MONROY-MARTINEZ
VERONICA MONROY-MARTINEZ
LALourdes Agredano
Lourdes Agredano
LJLuis Jimenez-Garcia
Luis Jimenez-Garcia
BRBlanca H Ruiz-Ordaz
Blanca H Ruiz-Ordaz
To date, no safe vaccine or antivirals for Zika virus (ZIKV) infection have been found. The pathogenesis of severe Zika, where host and viral factors participate, remains unclear. For the control of Zika, it is important to understand how ZIKV interacts with different host cells. Knowledge of the targeted cellular pathways which allow ZIKV to productively replicate and/or establish prolonged viral persistence contributes to novel vaccines and therapies. Monocytes and endothelial vascular cells are the main ZIKV targets. During the infection process, cells are capable of releasing extracellular vesicles (EVs). EVs are mediators of intercellular communication. We found that mosquito EVs released from ZIKV-infected (C6/36) cells carry viral RNA and ZIKV-E protein and are able to infect and activate naïve mosquito and mammalian cells. ZIKV C6/36 EVs promote the differentiation of naïve monocytes and induce a pro-inflammatory state with tumor necrosis factor-alpha (TNF-α) mRNA expression. ZIKV C6/36 EVs participate in endothelial vascular cell damage by inducing coagulation (TF) and inflammation (PAR-1) receptors at the endothelial surface of the cell membranes and promote a pro-inflammatory state with increased endothelial permeability. These data suggest that ZIKV C6/36 EVs may contribute to the pathogenesis of ZIKV infection in human hosts.

30 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JGJanet García-Pillado
Janet García-Pillado
PMPedro Pablo Martínez-Rojas
Pedro Pablo Martínez-Rojas
EQelizabeth quiroz
elizabeth quiroz
CCCARLOS CABELLO-GUTIERREZ
CARLOS CABELLO-GUTIERREZ
MLMarcela Lizano
Marcela Lizano
BRBlanca H Ruiz-Ordaz
Blanca H Ruiz-Ordaz
Dengue is the most prevalent arthropod-borne viral disease, caused by infection with dengue virus (DENV). Severe dengue is characterized by significant vasculopathy involving a proinflammatory and procoagulant state associated with increased vascular permeability. However, the host–virus interactions driving this process remain incompletely elucidate. Monocytes are primary target cells during DENV infection and actively release extracellular vesicles, like microparticles (MPs), mediating intercellular communication contributing to dengue pathogenesis. Here, we evaluated whether MPs released by DENV-infected monocytes represent a previously underappreciated mechanism contributing to dengue-associated vascular dysfunction. The vascular endothelium plays a determining role in the response to injury because it functions as a regulatory interface during hemostasis (coagulation–fibrinolysis–inflammation) and by preserving endothelial barrier. We found that these vesicles transport viral components capable of mediating DENV endothelial vascular cells (EVC) infection, while simultaneously exhibiting a procoagulant profile promoting thrombin generation and cell activation. DENV-infected Mø MPs interaction induces a shift toward a procoagulant, proinflammatory, and proadherent phenotype, characterized by increased expression of PAR-1, TF, ICAM-1, and VCAM-1, reflecting the establishment of a sustained EVC activation that compromises vascular barrier integrity, leading to increased permeability, a hallmark of DENV-associated vasculopathy and a central event in the progression to severe dengue.

Verified
Journal Article
Open access
PDF file
JGJanet García-Pillado
Janet García-Pillado
PMPedro Pablo Martínez-Rojas
Pedro Pablo Martínez-Rojas
EQelizabeth quiroz
elizabeth quiroz
CCCARLOS CABELLO-GUTIERREZ
CARLOS CABELLO-GUTIERREZ
MLMarcela Lizano
Marcela Lizano
BRBlanca H Ruiz-Ordaz
Blanca H Ruiz-Ordaz
Dengue is the most prevalent arthropod-borne viral disease, caused by infection with the dengue virus (DENV). Severe dengue is characterized by significant vasculopathy involving a proinflammatory and procoagulant state associated with increased vascular permeability. However, the host–virus interactions driving this process remain incompletely elucidated. Monocytes (Mø) are primary target cells during DENV infection and actively release extracellular vesicles, like microparticles (MPs), mediating intercellular communication, contributing to dengue pathogenesis. Here, we evaluated whether MPs released by DENV-infected monocytes represent a previously underappreciated mechanism contributing to dengue-associated vascular dysfunction. The vascular endothelium plays a determining role in the response to injury because it functions as a regulatory interface during hemostasis (coagulation–fibrinolysis–inflammation) and by preserving the endothelial barrier. We found that these vesicles transport viral proteins (E and NS1), exhibit a procoagulant profile that promotes thrombin generation, and enhance endothelial vascular cell (EVC) activation. DENV-infected THP-1 Mø MPs interaction induces a shift toward a procoagulant, proinflammatory, and proadherent phenotype, characterized by increased expression of PAR-1, TF, ICAM-1, and VCAM-1, reflecting the establishment of a sustained HMEC-1 EVC activation that compromises vascular barrier integrity. This leads to increased permeability, a hallmark of DENV-associated vasculopathy and a central event in the progression to severe dengue.